Acute liver failure is a severe liver disorder that poses considerable global challenges. Previous studies on Bifidobacterium longum R0175 have mainly focused on its psychotropic functions. The current research focused on the protective efficacy of B. longum R0175 against acute liver failure caused by d-galactosamine (d-GalN) in rats and further tested the hypothesis that B. longum R0175 exerted liver-protective effects by affecting the intestinal microbiota and fecal metabolites and by inhibiting inflammation. We found that oral gavage of B. longum R0175 markedly reduced the severity of liver injury in d-GalN-treated rats, as evidenced by decreased serum levels of aspartate aminotransferase (AST) and total bile acids (TBAs) (P < 0.05). Moreover, the plasma concentrations of proinflammatory cytokines (interleukin 1β [IL-1β] and tumor necrosis factor-α [TNF-α]) and chemokines (granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophage chemoattractant protein 1 [MCP-1], chemokine [C-X-C motif] ligand 1 [CXCL1], chemokine [C-C motif] ligand 5 [CCL5], and macrophage inflammatory protein-1α [MIP-1α]) were also markedly reduced (P < 0.05). Pretreatment with B. longum R0175 partially reversed the gut microbiota dysbiosis in rats with liver injury by increasing the relative abundances of potentially beneficial bacteria, such as Alloprevotella spp., and decreasing the relative abundances of potentially harmful bacteria, such as Acetatifactor muris, Butyricimonas spp., and Oscillibacter spp. Furthermore, B. longum R0175 administration partially improved the metabolic function of the intestinal microbes, as indicated by the decreased level of lithocholic acid found in the feces.IMPORTANCE Our research investigated the protective and preventive roles of B. longum R0175 in a rat model of acute liver failure. The results illustrated that this probiotic strain exhibited protective effects in rats with acute liver failure. Thus, B. longum R0175 showed clinical application prospects that required further exploration.

中文翻译：

---

长双歧杆菌R0175保护大鼠免受d-半乳糖胺诱导的急性肝功能衰竭。

急性肝衰竭是一种严重的肝脏疾病，带来了巨大的全球挑战。先前对长双歧杆菌R0175的研究主要集中在其精神功能上。目前的研究集中在长双歧杆菌R0175对大鼠中的d-半乳糖胺（d-GalN）引起的急性肝衰竭的保护作用，并进一步验证了长双歧杆菌R0175通过影响肠道菌群和肝脏发挥保护作用的假设。粪便代谢产物并通过抑制炎症。我们发现，经长双歧杆菌R0175进行口腔管饲显着降低了d-GalN治疗的大鼠的肝损伤严重程度，这通过降低血清中的天冬氨酸转氨酶（AST）和总胆汁酸（TBAs）来证明（P <0.05）。此外，血浆中促炎细胞因子（白介素1β[IL-1β]和肿瘤坏死因子-α[TNF-α]）和趋化因子（粒细胞-巨噬细胞集落刺激因子[GM-CSF]，巨噬细胞趋化蛋白1 [MCP-1] ]，趋化因子[CXC基序]配体1 [CXCL1]，趋化因子[CC基序]配体5 [CCL5]和巨噬细胞炎性蛋白1α[MIP-1α]）也显着减少（P <0.05）。用长双歧杆菌R0175预处理可通过增加潜在有益细菌（如Alloprevotella spp。）的相对丰度，并减少潜在有害细菌（如Acetatifactor muris，Butyricimonas spp）的相对丰度，部分逆转肝损伤大鼠的肠道微生物群失调。 。和Oscillibacter spp。此外，B。长粪R0175的施用可部分改善肠道微生物的代谢功能，这在粪便中发现的石胆酸水平降低即可。重要信息我们的研究调查了长鼻芽孢杆菌R0175在急性肝衰竭大鼠模型中的保护和预防作用。结果表明该益生菌菌株在急性肝衰竭大鼠中显示出保护作用。因此，长双歧杆菌R0175显示出需要进一步探索的临床应用前景。